GO 17A3
Alternative Names: GO-17A3Latest Information Update: 04 Feb 2021
At a glance
- Originator GO Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Malignant melanoma; Sarcoma
Most Recent Events
- 22 Jan 2021 Early research in Malignant melanoma in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
- 22 Jan 2021 Early research in Sarcoma in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
- 19 Jan 2021 GO 17A3 is available for licensing as of 22 Jan 2021. https://gotherapeutics.com/partnerships/ (GO Therapeutics website, January 2021)